Replimune stock upgraded to Outperform by Leerink on FDA acceptance of BLA
PositiveFinancial Markets

Replimune's stock has received an upgrade to 'Outperform' by Leerink following the FDA's acceptance of its Biologics License Application (BLA). This is significant as it indicates strong confidence in Replimune's potential to succeed in the market, which could lead to increased investor interest and potentially higher stock prices. The FDA's acceptance is a crucial step in the approval process, highlighting the company's advancements in the biotech sector.
— Curated by the World Pulse Now AI Editorial System